

## Product datasheet for **TL314054V**

### CDC23 Human shRNA Lentiviral Particle (Locus ID 8697)

#### Product data:

Product Type:	shRNA Lentiviral Particles
Product Name:	CDC23 Human shRNA Lentiviral Particle (Locus ID 8697)
Locus ID:	8697
Synonyms:	ANAPC8; APC8; CUT23
Vector:	pGFP-C-shLenti (TR30023)
Format:	Lentiviral particles
Components:	CDC23 - Human shRNA lentiviral particles (4 unique 29mer target-specific shRNA, 1 scramble control), 0.5 ml each, >10 <sup>7</sup> TU/ml.
RefSeq:	<a href="#">BC010944</a> , <a href="#">NM_004661</a> , <a href="#">NM_004661.1</a> , <a href="#">NM_004661.2</a> , <a href="#">NM_004661.3</a> , <a href="#">BC010944.1</a> , <a href="#">BC005258</a> , <a href="#">BC017713</a> , <a href="#">NM_004661.4</a>
UniProt ID:	<a href="#">Q9UJX2</a>
Summary:	The protein encoded by this gene shares strong similarity with <i>Saccharomyces cerevisiae</i> Cdc23, a protein essential for cell cycle progression through the G2/M transition. This protein is a component of anaphase-promoting complex (APC), which is composed of eight protein subunits and highly conserved in eukaryotic cells. APC catalyzes the formation of cyclin B-ubiquitin conjugate that is responsible for the ubiquitin-mediated proteolysis of B-type cyclins. This protein and 3 other members of the APC complex contain the TPR (tetraatricopeptide repeat), a protein domain important for protein-protein interaction. [provided by RefSeq, Jul 2008]
shRNA Design:	These shRNA constructs were designed against multiple splice variants at this gene locus. To be certain that your variant of interest is targeted, please contact <a href="mailto:techsupport@origene.com">techsupport@origene.com</a> . If you need a special design or shRNA sequence, please utilize our <a href="#">custom shRNA service</a> .



[View online »](#)

**Performance  
Guaranteed:**

OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples.

For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at [techsupport@origene.com](mailto:techsupport@origene.com). Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred).